A Study of LY3361237 in Participants With Psoriasis

Lilly

Status and phase

Completed

Phase 1

Conditions

Psoriasis

Treatments

Drug: Placebo

Drug: LY3361237

Study type

Interventional

Funder types

Industry

Identifiers

NCT04975295

I9S-MC-BTAC (Other Identifier)

2019-003187-40 (EudraCT Number)

17291

Details and patient eligibility

About

The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.

Enrollment

21 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Have chronic plaque psoriasis for at least 6 months
Be willing and able to undergo skin biopsies
Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²)
Female participants must agree to use birth control during the study

Exclusion criteria

Have had certain types of infection within the last six months
Have a clinically significant active infection, or recent acute active infection within the last 30 days
Have other serious or unstable illnesses
Have a history of organ or bone marrow transplant
Have received any live vaccine within the last 4 weeks prior to screening
Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1
Have received topical psoriasis treatment within 14 days prior to study day 1
Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1